Wednesday, 12 March 2025 11:00 AM
Class Action
WASHINGTON, DC / ACCESS Newswire / March 12, 2025 / Investors who suffered financial losses on shares of Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI) acquired between August 7, 2024, and February 24, 2025 (the "Class Period"), are encouraged to contact Cohen Milstein Sellers & Toll PLLC regarding a recently filed securities class action lawsuit.
To explore your legal options, click here to speak with a Cohen Milstein representative or reach out to Partner Molly Bowen at [email protected].
CASE BACKGROUND: Maravai is a biotechnology company that provides innovative solutions for drug development, diagnostics, and vaccine research. According to a complaint filed in the U.S. District Court for the Southern District of California, Maravai and specific current and former executives made materially false and misleading statements related to internal controls, revenue recognition, and goodwill valuation, violating Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
The lawsuit specifically alleges that throughout the Class Period, the Defendants:
Failed to maintain adequate internal controls over financial reporting, particularly concerning revenue recognition;
Improperly recognized revenue for certain transactions during fiscal 2024;
Overstated the Company's goodwill value; and
Issued statements about Maravai's financial health and business outlook that were materially misleading and lacked a reasonable basis.
On February 25, 2025, Maravai disclosed that it was postponing its earnings release and delaying the filing of its annual report due to revenue recognition issues and a potential non-cash impairment charge. Following this announcement, Maravai's stock price dropped approximately 21.7%, leading to significant investor losses.
NEXT STEPS: Investors who purchased MRVI shares during the Class Period and experienced substantial losses may be eligible to serve as lead plaintiff in this litigation. The deadline to seek appointment as lead plaintiff is May 5, 2025. Investors do not need to serve as lead plaintiff to participate in a potential recovery.
ABOUT COHEN MILSTEIN: With a team of more than 100 attorneys across eight offices, Cohen Milstein is among the nation's leading plaintiff-side law firms, with extensive experience in securities fraud litigation. The firm has successfully secured billions of dollars for investors, including a $1 billion recovery in In re Wells Fargo & Company Securities Litigation as co-lead counsel. Recognized by top legal publications such as The National Law Journal, Law360, Chambers USA, and The Legal 500, Cohen Milstein continues to be a premier advocate for investors. For more information, visit www.cohenmilstein.com.
Past results do not guarantee a similar outcome. This may be considered Attorney Advertising.
CONTACT INFORMATION:
Molly Bowen, Esq.
Cohen Milstein Sellers & Toll PLLC
Washington, D.C.
Office Email: [email protected]
Website: www.cohenmilstein.com
SOURCE: Cohen Milstein Sellers & Toll PLLC